Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Solid Tumors × ridaforolimus × Clear all

Phase

Status

Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 2 Solid Tumors 1 Ovarian Neoplasms 1 Neoplasms 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Advanced Cancers 1

Interventions

Paclitaxel 4 pembrolizumab 2 zansecimab 1 tocilizumab 1 tivozanib 1 temsirolimus 1 spartalizumab 1 ridaforolimus 1 parsaclisib 1 olaparib 1 obinutuzumab 1 motesanib diphosphate 1 liposomal doxorubicin 1 itacitinib 1 epacadostat 1 durvalumab 1 birinapant 1 atezolizumab 1 Vertebroplasty 1 Temozolomide 1 TAK-981 1 Ramucirumab 1 Panobinostat 1 Oxaliplatin 1 Leucovorin 1 Kyphoplasty 1 IT-101 1 INCB039110 1 Gemcitabine 1 Fluorouracil 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01431534 2019-03-01

MK-8669-056

Merck Sharp & Dohme LLC

Phase 1 Terminated

20 enrolled 10 charts

Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡